Revenue and Profitability - The company's revenue for Q1 2025 was ¥8,188,968.92, a decrease of 4.85% compared to ¥8,606,045.10 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥57,499,070.16, an improvement from a loss of ¥83,177,667.08 in the previous year[3] - The basic and diluted earnings per share were both -¥0.10, an improvement from -¥0.14 in the same period last year[3] - Net loss for Q1 2025 was CNY 57,499,070.16, an improvement of 30.94% compared to a net loss of CNY 83,177,667.08 in Q1 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities was a negative ¥62,024,952.61, compared to a negative ¥89,720,647.28 in the same period last year[3] - The company’s cash inflow from operating activities totaled CNY 2,477,134.27 in Q1 2025, compared to CNY 5,819,313.65 in Q1 2024[19] - The net cash flow from investing activities was -$259,625,660.39, indicating significant cash outflow for investments[20] - The total cash inflow from financing activities was $6,884,523.15, a decrease from $7,215,958.35 in the previous period[20] - The net cash flow from financing activities was $5,547,866.95, compared to $4,734,864.59 previously, showing an increase[20] - The net increase in cash and cash equivalents was -$316,760,939.87, a significant decline from -$86,199,363.71 in the prior period[20] - The ending balance of cash and cash equivalents was $597,185,628.32, down from $1,129,626,308.86 at the beginning of the period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,873,297,152.47, a decrease of 2.47% from ¥1,920,817,174.25 at the end of the previous year[4] - Total current assets as of March 31, 2025, amounted to CNY 1,823,300,104.90, a decrease from CNY 1,870,110,649.46 as of December 31, 2024[12] - Total liabilities decreased to CNY 103,054,740.11 in Q1 2025 from CNY 110,033,961.16 in Q1 2024[14] - The equity attributable to shareholders decreased by 2.24%, from ¥1,810,783,213.08 to ¥1,770,242,412.36[4] - Total equity attributable to shareholders was CNY 1,770,242,412.36 in Q1 2025, down from CNY 1,810,783,213.08 in Q1 2024[14] Research and Development - Research and development expenses totaled ¥60,674,466.51, down 28.41% from ¥84,752,226.60 year-on-year[3] - The ratio of R&D expenses to revenue decreased by 243.87 percentage points, from 984.80% to 740.93%[3] - R&D expenses for Q1 2025 were CNY 60,674,466.51, a decrease of 28.43% from CNY 84,752,226.60 in Q1 2024[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,559[8] Inventory and Accounts Management - The company reported a significant increase in inventory, although specific figures were not disclosed[12] - The company is actively managing its accounts payable, which decreased to CNY 54,574,331.75 from CNY 59,963,520.00[13] - Accounts receivable increased to CNY 173,587,883.14 from CNY 165,341,591.44, indicating a growth of approximately 7.5%[12] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[20] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[11]

Core Insights - Yifang Biotechnology (Shanghai) Co., Ltd. reported a revenue of 169 million yuan for 2024, a year-on-year decrease of 9.02%, and a net loss of 240 million yuan, which is a 15.41% reduction in losses compared to the previous year [1] - The company has made significant progress in its innovative drug development pipeline, although it has not yet achieved profitability [1][2] - The decline in revenue is primarily attributed to reduced income from technology licensing and the lack of substantial sales from new products [1] Financial Performance - Total revenue for 2024 was 169 million yuan, down 9.02% year-on-year [1] - Net loss for the year was 240 million yuan, with a year-on-year improvement of 15.41% [1] - Cumulative unabsorbed losses reached 2.545 billion yuan [1] Product Development - Yifang Biotechnology has received approval for two products: Beifutine (brand name: Saimeina) and Gexuolei (brand name: Anfangning) [1] - The company is advancing its pipeline with several key products, including D-2570 (a TYK2 inhibitor) for moderate to severe psoriasis, which has shown significant efficacy in clinical trials [2] - Other products in development include D-0502 (an oral SERD for breast cancer) and D-0120 (a URAT1 inhibitor), both of which are progressing through clinical trials [2] Commercialization Strategy - The company relies on technology licensing and product sharing for revenue generation [1] - Yifang Biotechnology plans to leverage partner channels for commercialization while exploring its own sales model to accelerate product value realization [2] - The sales team has not yet been established for products outside of licensed offerings, indicating a need for further development in this area [2]

（二）募投项目先期投入及置换情况 报告期内，公司不存在募投项目先期投入及置换情况。 （三）使用闲置募集资金暂时补充流动资金情况实施方式 （一）募集资金投资项目的资金使用情况 截至2024年12月31日，公司募集资金投资项目（以下简称"募投项目"）的资金使用情况详见附表1： 《募集资金使用情况对照表》。 截至2024年12月31日，公司不存在以闲置募集资金暂时补充流动资金的情况。 （四）对闲置募集资金进行现金管理及投资相关产品情况 公司于2023年8月21日召开第一届董事会2023年第四次会议及第一届监事会2023年第三次会议，审议通 过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司使用不超过人民币10亿元（包含本 数）的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、保本型的理财产品或存款类产 品（包括但不限于协定性存款、结构性存款、定期存款、大额存单等）。使用期限自董事会审议通过之 日起12个月内有效，在上述额度和期限内，资金可循环滚动使用。闲置募集资金现金管理到期后将归还 至募集资金专户。 公司于2024年8月21日召开第二届董事会2024年第五次会议及第二届监事会2024年第五次会 ...

Company Overview - The company is an innovative drug development enterprise focused on the research and commercialization of new drugs, with all products being independently developed and holding global intellectual property rights [8] - The company has established a comprehensive research and development system covering the entire drug development process, including drug chemistry, pharmacology, clinical research, and regulatory affairs [22] Financial Performance - In 2024, the company reported a net loss attributable to shareholders of 240.20 million yuan, with a cumulative unremedied loss of 2.54492 billion yuan [7] - The company does not plan to distribute cash dividends or issue bonus shares for the 2024 fiscal year [7] Product Pipeline - The company has two authorized products, Beifu Tini and Gesorese, which have been approved for market entry, while other products are still in clinical development [6][9] - Beifu Tini is a third-generation EGFR tyrosine kinase inhibitor for treating EGFR mutation-positive non-small cell lung cancer, with its second-line indication approved in 2023 and included in the National Medical Insurance Directory [9][10] - Gesorese is a KRAS G12C inhibitor for treating various cancers, with its NDA accepted in December 2023 and approved in November 2024 [11][12] Market Overview - The global pharmaceutical market has shown stable growth, increasing from $1,266.7 billion in 2018 to $1,495 billion in 2022, with a compound annual growth rate (CAGR) of 4.2% [33] - The Chinese pharmaceutical market is expected to grow at a CAGR of 8.1% from 2022 to 2025, reaching 196.27 billion yuan by 2025 [33] - The global oncology drug market has grown from $110.6 billion in 2017 to $181.7 billion in 2021, with a CAGR of 13.2%, and is projected to reach $484.5 billion by 2030 [36] Clinical Trials and Research - The company is conducting multiple clinical trials for its products, including ongoing phase III trials for Taragarestrant and D-0120, which are aimed at treating breast cancer and hyperuricemia, respectively [17][19] - D-2570, a selective TYK2 inhibitor for treating psoriasis, has shown promising results in clinical trials and is expected to provide a new treatment option for autoimmune diseases [20] Competitive Landscape - The company faces competition from established pharmaceutical firms with stronger financial resources and market experience, which may impact its ability to commercialize its products effectively [5] - The innovative drug development industry is characterized by high investment, long cycles, and significant risks, with many products facing uncertainty in their development and market acceptance [4][5]

公司代码：688382 公司简称：益方生物 益方生物科技（上海）股份有限公司 2024年度内部控制评价报告 益方生物科技（上海）股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于 ...

益方生物科技（上海）股份有限公司 2024 年度会计师事务所履职情况评估报告 益方生物科技（上海）股份有限公司（以下简称"公司"）聘请立信会计师 事务所（特殊普通合伙）作为公司 2024 年度财务及内部控制审计机构。根据财 政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务所管理办法》， 公司对立信会计师事务所（特殊普通合伙）2024 年审计过程中的履职情况进行 评估，具体情况如下： 1、资质条件 一、会计师事务所基本情况 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗 潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改制 的特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。 立信是国际会计网络 BDO 的成员所，长期从事证券服务业务，新证券法实施前 具有证券、期货业务许可证，具有 H 股审计资格，并已向美国公众公司会计监 督委员会（PCAOB）注册登记。 截至 2024 年末，立信拥有合伙人 296 名、注册会计师 2,498 名、从业人员 总数 10,021 名，签署过证券服务业务审计报告的注册会计师 743 名。 立信 ...

益方生物科技（上海）股份有限公司 董事会审计委员会2024年度履职情况报告 根据中国证监会和上海证券交易所《上市公司治理准则》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》等有关规定，益方生物科技（上 海）股份有限公司（以下简称"公司"）董事会审计委员会本着勤勉尽责的原则， 认真履行了审计委员会监督职责。现对公司董事会审计委员会 2024 年度的履职情况 汇报如下： 一、审计委员会基本情况 公司董事会审计委员会由独立董事戴欣苗女士、独立董事严嘉先生及董事王质 蕙女士组成，其中主任委员由独立董事戴欣苗女士担任。 审计委员会各成员具有能够胜任审计委员会工作职责的专业知识和商业经验， 符合上海证券交易所的规定及相关制度的要求。 二、公司董事会审计委员会 2024 年度会议召开情况 2024 年度，董事会审计委员会共召开 4 次会议，全体委员本着勤勉尽责的原则， 认真履行职责，均出席了会议，积极对相关议案发表意见，具体内容如下： | 序号 | | | 召开时间 | | | | 审议议案 | | | --- | --- | --- | --- | --- | --- | --- | --- | - ...

益方生物科技（上海）股份有限公司董事会审计委员会 对会计师事务所履行监督职责情况的报告 益方生物科技（上海）股份有限公司（以下简称"公司"）聘请立信会计师 事务所（特殊普通合伙）作为公司 2024 年度审计机构。根据财政部、国务院国 有资产监督管理委员会、中国证券监督管理委员会颁布的《国有企业、上市公司 选聘会计师事务所管理办法》，公司审计委员会切实对立信会计师事务所（特殊 普通合伙）在 2024 年度的审计工作情况履行了监督职责。具体情况如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 立信会计师事务所（特殊普通合伙）（以下简称"立信会计师事务所"）由我 国会计泰斗潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首 家完成改制的特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为 朱建弟先生。立信是国际会计网络 BDO 的成员所，长期从事证券服务业务，新 证券法实施前具有证券、期货业务许可证，具有 H 股审计资格，并已向美国公 众公司会计监督委员会（PCAOB）注册登记。 截至 2024 年末，立信拥有合伙人 296 名、注册会计师 2,498 ...

证券代码：688382 证券简称：益方生物 公告编号：2025-018 益方生物科技（上海）股份有限公司 关于公司会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会计政策变更是根据财政部相关规定进行的变更，不会对益方生 物科技（上海）股份有限公司（以下简称"公司"）财务状况和经营 成果产生重大影响。 2023 年 10 月 25 日，财政部发布了《企业会计准则解释第 17 号》（财会 〔2023〕21 号），明确了关于流动负债与非流动负债的划分、关于供应商融资 安排的披露以及关于售后租回交易的会计处理等要求，上述解释规定自 2024 年 1 月 1 日起施行。公司自 2024 年 1 月 1 日起执行该事项相关的会计处理。执行 该规定未对公司财务状况和经营成果产生重大影响。 （二）执行《企业数据资源相关会计处理暂行规定》的具体情况 2023 年 8 月 1 日，财政部发布了《企业数据资源相关会计处理暂行规定》 （财会〔2023〕11 号），适用于符合企业会计准则相关规定确认为无形资产 ...

证券代码：688382 证券简称：益方生物 公告编号：2025-017 益方生物科技（上海）股份有限公司 2024 年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求（2022 年修订）》以及《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》的相关规定，益方生物科技（上 海）股份有限公司（以下简称"公司"或"益方生物"）董事会将 2024 年度募 集资金存放与使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会于 2022 年 4 月 1 日出具的《关于同意益方生 物科技（上海）股份有限公司首次公开发行股票注册的批复》（证监许可（2022） 682 号），公司获准向社会公开发行人民币普通股 11,500 万股，每股发行价格为 人民币 18.12 元，募集资金总额为 208,380.00 万元，扣除承销及保荐费用、发 行 ...